ABR Nuclear Radiology study materials
ABR Nuclear Radiology study resources

ABR Nuclear Radiology study plan

ABR Nuclear Radiology · Give each week a clear focus.

8 weeks · About 6 hours per week

Week 1

Physics, Instrumentation, and Radiation Detection

  • Derive and apply decay, activity, and half-life relationships to calculate residual activity, daughter ingrowth, and specific activity for Tc-99m, F-18, Ga-68, Lu-177, and I-131.

  • Trace the scintillation detection signal chain from crystal through light guide, photomultiplier, preamplifier, and pulse-height analyzer, and predict how each stage changes energy resolution and count-rate linearity.

  • Compare NaI(Tl), CZT, and PET detector designs on stopping power, energy resolution, timing resolution, and dead-time behavior, and select the best detector for a stated clinical task.

  • Compute spatial resolution and sensitivity tradeoffs across parallel-hole, pinhole, converging, and diverging collimator geometries, and predict image appearance when septal thickness or hole length changes.

  • Distinguish photopeak, Compton, and backscatter events and explain how energy window width and scatter correction alter contrast and quantification.

Your checkpoint

A one-page physics and instrumentation formula sheet covering decay, collimator geometry, resolution, and detector performance, plus a 30-item self-written quiz scored at 80% or higher.

Week 2

Physics, Instrumentation, and Radiation Detection & Radiopharmacy and Radiopharmaceutical Chemistry

  • Perform and interpret daily and quarterly camera QC calculations, including intrinsic and extrinsic uniformity, spatial resolution, energy peaking, and center of rotation, and state the corrective action for each failure pattern.

  • Explain cyclotron production routes and generator elution chemistry for Tc-99m, Ga-68, and Rb-82, and predict eluate purity problems from parent breakthrough, alumina leakage, or elution timing errors.

  • Map biodistribution and clearance mechanisms, including renal tubular secretion, hepatobiliary excretion, receptor-mediated uptake, and bone chemisorption, to expected normal scan appearance and timing.

  • Describe radiopharmaceutical preparation controls, including radionuclidic purity, radiochemical purity testing methods, sterility, and endotoxin limits, and identify when a batch must be rejected.

Your checkpoint

A radiopharmacy and QC reference table listing production method, parent half-life, elution or purity limits, normal biodistribution, and critical organ for at least 10 commonly used agents, plus 20 self-written items scored at 80% or higher.

Week 3

Radiopharmacy and Radiopharmaceutical Chemistry & Radiation Safety, Dosimetry, and Regulations

  • Calculate absorbed organ dose and effective dose using the MIRD schema with residence times and S values, and compare dose estimates across competing diagnostic agents.

  • Apply 10 CFR 35 requirements to written directives, possession and use limits, training and signature authority, and required records, and identify the violation in a short scenario.

  • Compute patient release criteria from exposure rate and retained activity, and apply decision rules for pregnancy, breastfeeding interruption, and household contact restrictions.

  • Adjust administered activity for renal impairment, hepatic impairment, obesity, and pediatric patients using weight- or surface-area-based scaling, and justify each adjustment.

Your checkpoint

A dosimetry and regulatory worksheet containing 10 fully worked dose and release-calculation problems with unit-consistent answers, plus a one-page 10 CFR 35 compliance checklist.

Week 4

Radiation Safety, Dosimetry, and Regulations & Oncologic Imaging with PET/CT and SPECT/CT

  • Perform contamination survey math, including wipe-test efficiency correction, spill activity estimation, and decontamination endpoints, and sequence the response to a major versus minor spill.

  • Compare PET/CT and SPECT/CT acquisition and reconstruction choices, including time-of-flight, point-spread-function modeling, ordered-subset parameters, and CT technique for attenuation correction.

  • Diagnose attenuation-correction artifacts caused by oral or intravenous contrast, metallic hardware, patient motion, and CT-to-emission misregistration, and state the correction for each.

  • Apply Deauville and Lugano criteria to staging and restaging FDG PET/CT cases, and distinguish complete metabolic response from residual inflammatory uptake.

Your checkpoint

A 60-item timed mock examination covering domains 1 through 4 scored at 70% or higher, plus a written catalog of 10 attenuation and reconstruction artifacts with cause and fix.

Week 5

Oncologic Imaging with PET/CT and SPECT/CT

  • Differentiate physiologic from malignant uptake in brain, head and neck, thorax, abdomen, and pelvis on FDG PET/CT, and justify each call with anatomic or metabolic reasoning.

  • Select the appropriate oncologic tracer, including FDG, Ga-68 DOTATATE, PSMA-targeted agents, and F-18 NaF, for stated tumor types and clinical questions.

  • Quantify and interpret response using PERCIST-style SUV normalization and SUL peak measurement, and reconcile discordant PET and CT findings.

  • Evaluate incidental PET/CT findings such as thyroid, adrenal, and colonic uptake, and recommend a proportionate diagnostic next step.

  • Construct a structured PET/CT report that separates findings, impression, staging, and response category.

Your checkpoint

A 15-case interpretation log with structured reports, each including tracer rationale, staging or response category, and a documented differential for the dominant finding.

Week 6

Cardiovascular Nuclear Imaging

  • Interpret rest and stress perfusion patterns to separate reversible ischemia, fixed infarction, and balanced multivessel disease, and identify when quantification is required.

  • Recognize and correct common artifacts, including diaphragmatic and breast attenuation, patient motion, subdiaphragmatic bowel activity, left bundle branch block, and vasodilator side effects.

  • Compare myocardial blood flow and coronary flow reserve measurement by PET with relative perfusion scoring, and state the clinical settings where absolute flow changes management.

  • Select among FDG, Tl-201, and Tc-99m perfusion agents for viability assessment, and explain the metabolic and membrane mechanisms underlying each pattern.

  • Apply appropriate use criteria to choose stress testing modality for preoperative risk assessment, known coronary disease, and new-onset heart failure.

Your checkpoint

A 20-item cardiovascular self-assessment scored at 80% or higher, plus a one-page decision algorithm mapping clinical scenario to tracer, stress agent, and interpretation pitfall.

Week 7

Endocrine, Gastrointestinal, Genitourinary, and Pulmonary Nuclear Medicine & Skeletal, Infection, and Inflammation Imaging

  • Interpret thyroid and parathyroid scintigraphy, hepatobiliary imaging, gastrointestinal bleeding and Meckel studies, ventilation-perfusion lung scanning, and renal cortical and dynamic renography, and state the expected finding for each classic presentation.

  • Calculate split renal function and camera-based glomerular filtration rate from dynamic renography, and identify technical factors that invalidate the result.

  • Differentiate osteomyelitis from cellulitis, Charcot arthropathy, and prosthetic joint infection using three-phase bone scan, labeled leukocyte imaging, and FDG PET, and select the best test for each scenario.

  • Choose among Ga-67, labeled leukocyte, and FDG PET imaging for fever of unknown origin, sarcoidosis, vasculitis, and inflammatory bowel disease, and justify the choice by mechanism and biodistribution.

Your checkpoint

Two system-comparison tables covering endocrine/GI/GU/pulmonary and skeletal/infection imaging, plus a 25-item mixed quiz scored at 75% or higher.

Week 8

Neuroimaging and Radiopharmaceutical Therapy

  • Interpret dopamine transporter, brain perfusion, and FDG brain patterns to distinguish neurodegenerative dementias, movement disorders, and seizure foci from normal variant uptake.

  • Design a treatment and monitoring plan for I-131, Lu-177 DOTATATE, Ra-223, and Y-90 microsphere therapy, including activity selection, dosimetry method, and toxicity surveillance intervals.

  • Apply radiation safety requirements specific to therapy patients, including inpatient versus outpatient release, room and linen surveys, effluent handling, and written family instructions.

  • Integrate high-yield concepts across all eight domains into a single rapid-review framework, and convert weak mock-exam topics into a dated remediation list.

Your checkpoint

A full-length timed mock examination covering all eight domains scored at 75% or higher, plus a therapy safety checklist and a prioritized remediation list with target review dates.

Milestones

Week 2: Physics and instrumentation quiz at 80% or higher, with the formula sheet reviewed against every missed item; no unresolved calculation error remains in decay, collimator, or detector problems.

Week 4: Domain 1 through 4 mock examination at 70% or higher, with all dosimetry and release-criteria worksheet problems completed independently and checked for unit consistency.

Week 6: Cardiovascular self-assessment at 80% or higher and at least 15 oncologic cases dictated in structured format; artifacts and response categories identified without reference material.

Week 8: Full-length mock examination at 75% or higher across all eight domains, with every item below that threshold logged on the remediation list and scheduled before the exam date.